NCT02041260 2021-10-15A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line SettingThomas Jefferson UniversityPhase 2 Unknown43 enrolled